vs

Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and GCM Grosvenor Inc. (GCMG). Click either name above to swap in a different company.

Axsome Therapeutics, Inc. is the larger business by last-quarter revenue ($196.0M vs $177.1M, roughly 1.1× GCM Grosvenor Inc.). GCM Grosvenor Inc. runs the higher net margin — 32.8% vs -14.6%, a 47.4% gap on every dollar of revenue. On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs 7.2%). GCM Grosvenor Inc. produced more free cash flow last quarter ($175.0M vs $-18.7M). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs 27.5%).

Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.

GCM Grosvenor is an American alternative asset management firm, with approximately $76 billion in assets under management and approximately 530 professionals as of 2023.

AXSM vs GCMG — Head-to-Head

Bigger by revenue
AXSM
AXSM
1.1× larger
AXSM
$196.0M
$177.1M
GCMG
Growing faster (revenue YoY)
AXSM
AXSM
+57.9% gap
AXSM
65.0%
7.2%
GCMG
Higher net margin
GCMG
GCMG
47.4% more per $
GCMG
32.8%
-14.6%
AXSM
More free cash flow
GCMG
GCMG
$193.8M more FCF
GCMG
$175.0M
$-18.7M
AXSM
Faster 2-yr revenue CAGR
AXSM
AXSM
Annualised
AXSM
61.7%
27.5%
GCMG

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AXSM
AXSM
GCMG
GCMG
Revenue
$196.0M
$177.1M
Net Profit
$-28.6M
$58.2M
Gross Margin
Operating Margin
-13.8%
30.9%
Net Margin
-14.6%
32.8%
Revenue YoY
65.0%
7.2%
Net Profit YoY
61.9%
149.2%
EPS (diluted)
$-0.55
$0.23

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AXSM
AXSM
GCMG
GCMG
Q4 25
$196.0M
$177.1M
Q3 25
$171.0M
$135.0M
Q2 25
$150.0M
$119.7M
Q1 25
$121.5M
$125.8M
Q4 24
$118.8M
$165.3M
Q3 24
$104.8M
$122.9M
Q2 24
$87.2M
$117.0M
Q1 24
$75.0M
$108.9M
Net Profit
AXSM
AXSM
GCMG
GCMG
Q4 25
$-28.6M
$58.2M
Q3 25
$-47.2M
$10.5M
Q2 25
$-48.0M
$15.4M
Q1 25
$-59.4M
$463.0K
Q4 24
$-74.9M
$7.6M
Q3 24
$-64.6M
$4.2M
Q2 24
$-79.3M
$4.8M
Q1 24
$-68.4M
$2.1M
Operating Margin
AXSM
AXSM
GCMG
GCMG
Q4 25
-13.8%
30.9%
Q3 25
-27.0%
32.7%
Q2 25
-24.5%
16.1%
Q1 25
-46.9%
12.2%
Q4 24
-61.1%
26.4%
Q3 24
-59.8%
20.3%
Q2 24
-89.5%
17.8%
Q1 24
-89.7%
-14.7%
Net Margin
AXSM
AXSM
GCMG
GCMG
Q4 25
-14.6%
32.8%
Q3 25
-27.6%
7.8%
Q2 25
-32.0%
12.9%
Q1 25
-48.9%
0.4%
Q4 24
-63.1%
4.6%
Q3 24
-61.7%
3.4%
Q2 24
-91.0%
4.1%
Q1 24
-91.1%
2.0%
EPS (diluted)
AXSM
AXSM
GCMG
GCMG
Q4 25
$-0.55
$0.23
Q3 25
$-0.94
$0.16
Q2 25
$-0.97
$0.05
Q1 25
$-1.22
$-0.02
Q4 24
$-1.54
$0.09
Q3 24
$-1.34
$0.03
Q2 24
$-1.67
$0.04
Q1 24
$-1.44
$-0.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AXSM
AXSM
GCMG
GCMG
Cash + ST InvestmentsLiquidity on hand
$322.9M
$242.1M
Total DebtLower is stronger
$428.4M
Stockholders' EquityBook value
$88.3M
$27.0M
Total Assets
$689.8M
$813.8M
Debt / EquityLower = less leverage
15.87×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AXSM
AXSM
GCMG
GCMG
Q4 25
$322.9M
$242.1M
Q3 25
$325.3M
$182.7M
Q2 25
$303.0M
$136.3M
Q1 25
$300.9M
$94.5M
Q4 24
$315.4M
$89.5M
Q3 24
$327.3M
$98.4M
Q2 24
$315.7M
$73.9M
Q1 24
$331.4M
$41.9M
Total Debt
AXSM
AXSM
GCMG
GCMG
Q4 25
$428.4M
Q3 25
$429.3M
Q2 25
$430.2M
Q1 25
$431.1M
Q4 24
$432.0M
Q3 24
$432.9M
Q2 24
$433.8M
Q1 24
$384.0M
Stockholders' Equity
AXSM
AXSM
GCMG
GCMG
Q4 25
$88.3M
$27.0M
Q3 25
$73.7M
$-7.4M
Q2 25
$73.1M
$-12.3M
Q1 25
$53.2M
$-28.3M
Q4 24
$57.0M
$-27.6M
Q3 24
$92.9M
$-31.9M
Q2 24
$102.9M
$-28.5M
Q1 24
$144.0M
$-26.4M
Total Assets
AXSM
AXSM
GCMG
GCMG
Q4 25
$689.8M
$813.8M
Q3 25
$669.3M
$685.9M
Q2 25
$639.8M
$636.9M
Q1 25
$596.7M
$579.8M
Q4 24
$568.5M
$612.7M
Q3 24
$561.5M
$575.0M
Q2 24
$548.2M
$543.9M
Q1 24
$545.7M
$497.3M
Debt / Equity
AXSM
AXSM
GCMG
GCMG
Q4 25
15.87×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AXSM
AXSM
GCMG
GCMG
Operating Cash FlowLast quarter
$-18.7M
$183.5M
Free Cash FlowOCF − Capex
$-18.7M
$175.0M
FCF MarginFCF / Revenue
-9.6%
98.8%
Capex IntensityCapex / Revenue
0.0%
4.8%
Cash ConversionOCF / Net Profit
3.16×
TTM Free Cash FlowTrailing 4 quarters
$-93.9M
$326.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AXSM
AXSM
GCMG
GCMG
Q4 25
$-18.7M
$183.5M
Q3 25
$1.0M
$79.8M
Q2 25
$-32.4M
$42.0M
Q1 25
$-43.4M
$33.3M
Q4 24
$-26.2M
$148.8M
Q3 24
$-18.6M
$69.0M
Q2 24
$-30.1M
$17.5M
Q1 24
$-53.5M
$24.2M
Free Cash Flow
AXSM
AXSM
GCMG
GCMG
Q4 25
$-18.7M
$175.0M
Q3 25
$988.0K
$78.3M
Q2 25
$-32.4M
$40.8M
Q1 25
$-43.7M
$32.1M
Q4 24
$-26.2M
$132.0M
Q3 24
$-18.7M
$62.2M
Q2 24
$-30.2M
$12.8M
Q1 24
$-53.6M
$20.0M
FCF Margin
AXSM
AXSM
GCMG
GCMG
Q4 25
-9.6%
98.8%
Q3 25
0.6%
58.0%
Q2 25
-21.6%
34.1%
Q1 25
-36.0%
25.5%
Q4 24
-22.1%
79.9%
Q3 24
-17.9%
50.6%
Q2 24
-34.6%
10.9%
Q1 24
-71.4%
18.4%
Capex Intensity
AXSM
AXSM
GCMG
GCMG
Q4 25
0.0%
4.8%
Q3 25
0.0%
1.1%
Q2 25
0.0%
1.0%
Q1 25
0.3%
0.9%
Q4 24
0.0%
10.1%
Q3 24
0.1%
5.5%
Q2 24
0.1%
4.0%
Q1 24
0.1%
3.9%
Cash Conversion
AXSM
AXSM
GCMG
GCMG
Q4 25
3.16×
Q3 25
7.61×
Q2 25
2.72×
Q1 25
71.84×
Q4 24
19.54×
Q3 24
16.60×
Q2 24
3.64×
Q1 24
11.40×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AXSM
AXSM

Segment breakdown not available.

GCMG
GCMG

Asset Management1$108.6M61%
Management Service Incentive Performance Fees$61.7M35%
Management Service Incentive Carried Interest$5.1M3%
Service Other$1.8M1%

Related Comparisons